(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 34.71% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Alvotech's revenue in 2025 is $491,978,000.On average, 2 Wall Street analysts forecast ALVO's revenue for 2025 to be $190,846,819,851, with the lowest ALVO revenue forecast at $186,365,005,548, and the highest ALVO revenue forecast at $195,328,935,960. On average, 2 Wall Street analysts forecast ALVO's revenue for 2026 to be $256,148,514,183, with the lowest ALVO revenue forecast at $230,806,495,097, and the highest ALVO revenue forecast at $281,490,533,270.
In 2027, ALVO is forecast to generate $379,578,585,517 in revenue, with the lowest revenue forecast at $379,578,585,517 and the highest revenue forecast at $379,578,585,517.